Biocon Surges as Biocon Biologics Launches Yesintek (ustekinumab-kfce) in the U.S.
Biocon’s stock is witnessing a sharp rally following the launch of Yesintek (ustekinumab-kfce) in the United States by its subsidiary Biocon Biologics. The company’s shares are currently trading at Rs. 328.00, up by 2.21%, adding 7.10 points from its previous close of Rs. 320.90 on the Bombay Stock Exchange (BSE). The stock opened at Rs. … Read more
